Oculis Holding AG (OCS) Interest Expenses (2022 - 2026)
Oculis Holding AG's (OCS) quarterly Interest Expenses came in at -$42141.2 in Q1 2026, down 215.73% year-on-year from $36411.8 in Q1 2025, and up 6.44% quarter-over-quarter from -$45042.1 in Q4 2025.
Oculis Holding AG (OCS) Interest Expenses (2022 - 2026) Analysis & Trends
Oculis Holding AG's Interest Expenses history runs 5 years deep, the most recent figure standing at -$42141.2 for Q1 2026.
- On a quarterly basis, Interest Expenses fell 215.73% year-over-year to -$42141.2 in Q1 2026; TTM through Mar 2026 was -$135473.1, a 114.05% decrease from a year earlier, with the FY2025 full-year figure at $1.0 million, up 38.32% from the prior year.
- Interest Expenses rose to -$42141.2 in Q1 2026 per OCS's latest filing, from -$45042.1 in the prior quarter.
- Across five years, Interest Expenses topped out at $6.7 million in Q4 2022 and bottomed at -$1.7 million in Q2 2022.
- The 5-year median for Interest Expenses is -$15525.8 (2023), against an average of $291159.7.
- Across the five-year window, Interest Expenses surged 5149.09% in 2023 and sank 215.73% in 2026, its largest moves.
- Year by year, Interest Expenses stood at $6.7 million in 2022, then slumped by 122.17% to -$1.5 million in 2023, then surged by 99.0% to -$14839.8 in 2024, then tumbled by 203.52% to -$45042.1 in 2025, then climbed by 6.44% to -$42141.2 in 2026.
- Per Business Quant, the three latest OCS Interest Expenses figures stand at -$42141.2 (Q1 2026), -$45042.1 (Q4 2025), and -$35003.1 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 1.17 Bn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 69.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42,141.15 |
| Mar 31, 2026 | -42,141.15 |
| Dec 31, 2025 | -45,042.11 |
| Dec 31, 2025 | -45,042.11 |
| Sep 30, 2025 | -35,003.07 |
| Sep 30, 2025 | -35,003.07 |
| Jun 30, 2025 | -13,286.79 |
| Jun 30, 2025 | -13,286.79 |
| Mar 31, 2025 | -13,347.01 |
| Mar 31, 2025 | -13,347.01 |
| Dec 31, 2024 | -14,839.78 |
| Dec 31, 2024 | -14,839.78 |
| Sep 30, 2024 | -19,621.52 |
| Sep 30, 2024 | -19,621.52 |
| Jun 30, 2024 | -15,481.11 |
| Jun 30, 2024 | -15,481.11 |
| Mar 31, 2024 | -11,456.82 |
| Mar 31, 2024 | -11,456.82 |
| Dec 31, 2023 | -1.48 Mn |
| Dec 31, 2023 | -1.48 Mn |